Analysts Expect Sesen Bio, Inc. (NASDAQ:SESN) to Post -$0.09 EPS

Analysts expect that Sesen Bio, Inc. (NASDAQ:SESNGet Rating) will post ($0.09) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sesen Bio’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.13). Sesen Bio reported earnings per share of ($0.07) during the same quarter last year, which would suggest a negative year-over-year growth rate of 28.6%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Sesen Bio will report full-year earnings of ($0.32) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to ($0.19). For the next financial year, analysts expect that the company will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.35) to ($0.19). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Sesen Bio.

Sesen Bio (NASDAQ:SESNGet Rating) last announced its quarterly earnings results on Monday, February 28th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. The firm had revenue of $20.00 million during the quarter.

A number of equities research analysts have issued reports on SESN shares. StockNews.com started coverage on Sesen Bio in a research report on Wednesday, May 18th. They set a “hold” rating for the company. Zacks Investment Research raised Sesen Bio from a “hold” rating to a “strong-buy” rating and set a $0.50 target price for the company in a research report on Friday, May 13th.

Shares of Sesen Bio stock opened at $0.49 on Monday. The stock has a market capitalization of $98.63 million, a P/E ratio of 1.98 and a beta of 0.92. The stock has a 50 day moving average price of $0.54 and a two-hundred day moving average price of $0.73. Sesen Bio has a 12-month low of $0.37 and a 12-month high of $6.04.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Sesen Bio by 23.3% during the fourth quarter. BlackRock Inc. now owns 13,488,604 shares of the company’s stock worth $10,994,000 after buying an additional 2,553,282 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sesen Bio by 72.1% during the 4th quarter. Geode Capital Management LLC now owns 4,511,761 shares of the company’s stock worth $3,677,000 after purchasing an additional 1,890,771 shares during the last quarter. Morgan Stanley boosted its stake in shares of Sesen Bio by 243.1% during the 3rd quarter. Morgan Stanley now owns 653,437 shares of the company’s stock worth $518,000 after acquiring an additional 462,991 shares during the period. Renaissance Technologies LLC bought a new position in shares of Sesen Bio during the 1st quarter worth approximately $276,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Sesen Bio by 198.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 606,862 shares of the company’s stock worth $495,000 after acquiring an additional 403,606 shares during the period. Institutional investors and hedge funds own 24.29% of the company’s stock.

Sesen Bio Company Profile (Get Rating)

Sesen Bio, Inc, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors.

See Also

Get a free copy of the Zacks research report on Sesen Bio (SESN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sesen Bio (NASDAQ:SESN)

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.